Form 4: Fulgent Genetics CFO Sells Shares for Tax Obligations

Fulgent Genetics CFO Paul Kim disposed of 1,131 common shares at $22.17 each to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Paul Kim, the Chief Financial Officer and Treasurer of Fulgent Genetics, Inc. (FLGT), reported a transaction on September 1, 2025.
• The transaction involved the disposition of 1,131 shares of Fulgent Genetics common stock.
• The shares were disposed of at a price of $22.17 per share.
• This disposition was specifically to satisfy tax withholding obligations that arose upon the vesting of restricted stock units (RSUs) granted to Mr. Kim on February 28, 2022.
• Following this reported transaction, Paul Kim beneficially owns 336,861 shares of Fulgent Genetics common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine tax-related disposition of shares upon RSU vesting, which is a neutral event and does not reflect a discretionary sale by management or a change in company fundamentals.

Positives

• The transaction is a result of restricted stock units (RSUs) vesting, which indicates a prior grant of equity compensation to the CFO, aligning management's interests with shareholders.

Negatives

• A total of 1,131 common shares were disposed of, resulting in a minor reduction in the direct beneficial ownership of the CFO.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the underlying RSU vesting indicates continued alignment of management interests with shareholders through equity compensation.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by the CFO to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and generally do not indicate a change in management's outlook or warrant a change in investment recommendation. Investors should consider this a neutral event.

Keywords

Fulgent Genetics, FLGT, Paul Kim, CFO, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Compensation